Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Equillium Inc
EQ | US
2.79
USD-0.29
-9.42%
EQ | US
About Equillium Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
2.79
Open
2.61
High
2.99
Low
2.23
Equillium Inc. a clinical-stage biotechnology company develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001) a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6 which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium Inc. was formerly known as Attenuate Biopharmaceuticals Inc. and changed its name to Equillium Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla California.
View LessEQ | US
Risk
131.7
Sharpe
3.68
Luna's Score
57/100
Recommendation
Hold
Luna says (EQ | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
120.6%1 month
131.7%3 months
112.7%6 months
114.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
1.53
Price to book
1.71
Debt to equity
0.03
Debt to assets
0.01
Ent. to EBITDA
0.07
Ent. to rev.
0.13
PEG
-
Other Fundamentals
EBITDA
-9.58M
MarketCap
98.83M
MarketCap(USD)
98.83M
Div. yield
-
Op. margin
-0.72
Erngs. growth
-
Rev. growth
51.80
Ret. on equity
-33.67
Short ratio
1.81
Short perc.
0.87
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.36
Range1M
1.36
Range3M
1.52
Volumes: Market Activity
Rel. volume
3.87
Price X volume
7.72M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.07 | - | Cheaper |
| Ent. to Revenue | 0.13 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.71 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 112.70 | - | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 98.83M | - | Emerging |
